Search

Now showing items 1-10 of 40

Body mass does not affect clinical outcomes of therapy with abatacept in rheumatoid arthritis (RA) patients. A pan-european analysis of RA registries

2014- Gómez-Reino Carnota, Juan Jesús

Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in measures of disease activity in patients with psoriatic arthritis: Results from 3 phase 3, randomized, controlled trials

2014- Gómez-Reino Carnota, Juan Jesús

Positive effect of stringent criteria for PPD skin test on CZP patients

2014- Gómez-Reino Carnota, Juan Jesús

ADIPOKINES INDUCE INFLAMMATORY MEDIATORS IN CD4+T CELLS AND MODULATE THE CROSS TALK BETWEEN CD4+T LYMPHOCYTES AND CHONDROCYTES FROM OA PATIENTS

2014- Abella Cajigal, Vanesa; Gómez-Reino Carnota, Juan Jesús; Scotece, Morena; Gualillo, Oreste; Pino Mínguez, Jesús; [et al.]

Predictors of Discontinuation of Biologic DMARD Therapy Due to Remission in Patients with Rheumatoid Arthritis in a National Registry

2014- Gómez-Reino Carnota, Juan Jesús

Replication of PTPRC As Genetic Biomarker of Response to TNF Inhibitors in Patients with Rheumatoid Arthritis.

2014- Gómez-Reino Carnota, Juan Jesús; González Martínez-Pedrayo, Antonio; Ferreiro Iglesias, Aida

Clinical and Tissue Specificity of Antibodies Against Carbamylated Proteins in Patients with Rheumatoid Arthritis.

2014- Gómez-Reino Carnota, Juan Jesús; González Martínez-Pedrayo, Antonio; Montes Martínez, Ariana María; Pérez Pampín, Eva; Bóveda Fontán, María Dolores

Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials.

2014- Gómez-Reino Carnota, Juan Jesús

Long-Term Efficacy and Safety of Tocilizumab (TCZ) Monotherapy in Patients (PTS) with Rheumatoid Arthritis (RA) Previously Methotrexate (MTX) Naive or MTX Free for 6 Months Prior to Study Start

2014- Gómez-Reino Carnota, Juan Jesús

Change in Weight from Baseline with Apremilast, an Oral Phosphodiesterase 4 Inhibitor: Pooled Results from 3 Phase 3, Randomized, Controlled Trials

2014- Gómez-Reino Carnota, Juan Jesús

1
2
3
4